The UNC CERTs proposes to develop, test, validate, and disseminate a standardized, user-friendly software tool for obtaining doubly robust estimate of treatment effects in SAS(r). In one set of extensive simulations, doubly robust methods have been shown to provide additional insurance against bias due to confounding, maintaining a bias <1% and correct coverage of 95% confidence intervals despite omission of a key confounder and a moderate to strong prognostic factor from one of its two component models. The proposed SAS tool will incorporate a point-and-click windows interface and will make it easier for epidemiologists and biostatisticians to use this recently developed analytic method to reduce effects of confounding and selection bias in analyses of observational studies of the safety and effectiveness of drugs. Doubly robust methods are not currently available in standard software packages, necessitating the use of custom programming. The availability of an easy-to-use tool clearly will further investigators' efforts to close gaps in priority area research on comparative effectiveness, as explicitly mandated in Section 1013 of the Medicare Prescription Drug, Improvement, and Modernization Act (MMA, PL 1008-173).
Our aims focus on the class of estimators that includes doubly robust methods and other inverse probability of treatment weighted estimates (IPTW). We will develop, document, test and validate SAS macros with a graphical user interface for doubly-robust and IPTW methods, focusing on the case of a point exposure or treatment. We will conduct usability testing with participants in a causal modeling course at UNC. Responding to the RFA's strong encouragement of """"""""coordinated, complementary, and collaborative applications"""""""" (p. 7), we will collaborate explicitly with the Duke CERTs investigators to evaluate the usability of the SAS software tool in their analysis of the effectiveness of beta-blockers for which clinical trial evidence of effectiveness exists (carvedilol, metoprolol succinate, and bisoprolol fumarate) with that of older, off-patent beta-blockers in reducing mortality among patients with congestive heart failure. Finally, we will disseminate this tool through publications in technical and scientific journals, a website and through AHRQ, and the other CERTs, to as broad an audience as possible. Relevance: The Medicare Prescription Drug Benefit, Improvement, and Modernization Act calls for new scientific information to close gaps in our knowledge about the comparative effectiveness of drugs. Freely available, usable analytical software incorporating recent advances in statistical theory, as we propose to develop here, can help create that new scientific information. ? ? ?

Agency
National Institute of Health (NIH)
Institute
Agency for Healthcare Research and Quality (AHRQ)
Type
Research Demonstration--Cooperative Agreements (U18)
Project #
3U18HS010397-07S1
Application #
7072090
Study Section
Special Emphasis Panel (ZHS1-HSR-O (02))
Program Officer
Smith, Scott R
Project Start
1999-09-30
Project End
2007-09-29
Budget Start
2005-09-30
Budget End
2006-09-29
Support Year
7
Fiscal Year
2005
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Karve, Sudeep; Candrilli, Sean; Kappelman, Michael D et al. (2012) Healthcare utilization and comorbidity burden among children and young adults in the United States with systemic lupus erythematosus or inflammatory bowel disease. J Pediatr 161:662-670.e2
Funk, Michele Jonsson; Westreich, Daniel; Wiesen, Chris et al. (2011) Doubly robust estimation of causal effects. Am J Epidemiol 173:761-7
Dellon, Elisabeth P; Shores, Mitchell D; Nelson, Katherine I et al. (2010) Caregiver perspectives on discussions about the use of intensive treatments in cystic fibrosis. J Pain Symptom Manage 40:821-8
Dellon, Elisabeth P; Shores, Mitchell D; Nelson, Katherine I et al. (2010) Family caregiver perspectives on symptoms and treatments for patients dying from complications of cystic fibrosis. J Pain Symptom Manage 40:829-37
Gipson, Debbie S; Massengill, Susan F; Yao, Lynne et al. (2009) Management of childhood onset nephrotic syndrome. Pediatrics 124:747-57
MacHardy, Nathaniel; Miles, Paul V; Massengill, Susan F et al. (2009) Management patterns of childhood-onset nephrotic syndrome. Pediatr Nephrol 24:2193-201
Dellon, Elisabeth P; Shores, Mitchell D; Nelson, Katherine I et al. (2009) Caregivers' perspectives on decision making about lung transplantation in cystic fibrosis. Prog Transplant 19:318-25
Devine, Scott; West, Suzanne L; Andrews, Elizabeth et al. (2008) Validation of neural tube defects in the full featured--general practice research database. Pharmacoepidemiol Drug Saf 17:434-44
Dellon, Elisabeth P; Leigh, Margaret W; Yankaskas, James R et al. (2007) Effects of lung transplantation on inpatient end of life care in cystic fibrosis. J Cyst Fibros 6:396-402
Appel, Susan J; Harrell, Joanne S; Davenport, Marsha L (2005) Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults. J Am Acad Nurse Pract 17:535-41

Showing the most recent 10 out of 14 publications